EP0389598A1 - Energy substrate containing hydroxy carboxylic acid and glycerol ester - Google Patents
Energy substrate containing hydroxy carboxylic acid and glycerol esterInfo
- Publication number
- EP0389598A1 EP0389598A1 EP89910235A EP89910235A EP0389598A1 EP 0389598 A1 EP0389598 A1 EP 0389598A1 EP 89910235 A EP89910235 A EP 89910235A EP 89910235 A EP89910235 A EP 89910235A EP 0389598 A1 EP0389598 A1 EP 0389598A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- energy substrate
- hydroxy
- substrate according
- carboxylic acid
- glycerol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
Definitions
- the present invention relates to pharmaceutical sub ⁇ strates and pertains to the field of clinical nutrition. This field is concerned with all forms of enteral and parenteral nutrition of mammals.
- SUBSTITUTE SHEET as an energy source, which results in a more or less extreme protein catabolic situation.
- SUBSTITUTESHEET amino acids An advantage is gained when branched keto acids can replace partially, e.g., glucose. No experi ⁇ ments with branched keto acids as an energy-boost source have previously been carried out. Instead, trials with branched keto acids have been intended for the admini ⁇ stration of nitrogen-free amino acid substitutes to, for instance, uremics and those suffering from liver di ⁇ seases (DE 2335215, 2335216, US Patent Specification 4,100,161, 4,100,160, EP 0 227 545). It has been diffi- cult, however, in practice, to produce and store solu ⁇ tions which contain branched ⁇ -keto acids in free form, since such acids have an extremely poor stability.
- Acids bound to different carriers have also shown poor stability.
- One solution e.g. proposed in DE 2335215
- a concentrated solution which has been sterile-filtered and frozen.
- the keto-acid concentrate Prior to use, the keto-acid concentrate is thawed and diluted to the correct concentration.
- the significantly more dura ⁇ ble branched ⁇ -hydroxy acid homologues have also been used. These have been used, however, solely as nitrogen- free amino-acid substitutes (German Patent Speification 2335215 and 2335216).
- branched hydroxy acids By branched hydroxy acids is meant in the present description and claims branched amino acids (leucine, isoleucine and valine) these amino groups being substituted with hydroxy groups.
- the resul ⁇ tant acids can be converted to the respective ⁇ -keto acids, through specific enzymatic reactions.
- the enzymes taking part in these conversions are found generally in various organs of the majority of mammals, among them human beings.
- ⁇ -keto leucine The end products of ⁇ -keto leucine are acetyl-CoA and propionyl-CoA. This last mentioned is converted to succinyl-CoA, which is also an end product for ⁇ -keto valine. Succinyl-CoA is already present in the citrate cycle and also in the breathing chain for energy reco ⁇ very (NADH+H and FADH_) . Branched ⁇ -hydroxy acid can be used in the aforedescribed manner as a substitute energy substrate for branched ⁇ -keto acids.
- SUBSTITUTE SHEET Another possibility for branched ⁇ -hydroxy acids to generate energy, is to pass directly through the inner mitochondria membrane and into the matrix, where they are converted enzymatically (via a lactate dehydro- genase) to the respective ⁇ -keto acid.
- the reaction can be described as a shuttle in accordance with the follow ⁇ ing:
- This system is thought to be capable of gener- ating energy, partly through oxidation of the ⁇ -keto acid formed and partly through the delivery of cytosol- protons, which are able to enter the breathing chain directly as NADH + H + .
- peripheral catheter Furthermore, it is necessary to restrict the supply of calcium and mag ⁇ nesium, due to the risk of precipitation and subsequent blocking of the catheter. It must be considered par- ticularly riskful to supply large quantities of electro ⁇ lytes to a patient suffering from shock after, for instance, sepsis, with reduced renal excretion, inter alia, from the aspect of circulation. Neither is it possible to exclude a certain negative influence on transport processes out and into the mitochondria.
- the aforementioned drawbacks are avoided by the present invention, which enables large quantities of the branched hydroxy acids to be administered without need- ing to administer large quantities of electrolytes. This is achieved in accordance with the present invention, by administering the hydroxy acids in the form of esters • with an alcohol, and then particulary glycerol.
- the present invention relates to an energy substrate for nutrient supply to a mammal in a catabolic state, and is characterized in that the energy substrate contains at least one ester of glycerol and a hydroxy carboxylic acid having a branched carbon chain.
- R ⁇ is hydrogen or straight or branched alkyl or alkenyl
- R_ is straight or branched alkyl or al- kenyl
- R. is hydrogen
- 2 is always branched alkyl or alkenyl
- R., and R 2 together contain from 2 to 6 carbon atoms
- n is zero or 1.
- n in the formula is preferably zero, so that the hydroxy group will always sit in the ⁇ -position of the carboxyl group.
- the hydroxy group may also sit on the ⁇ -position, in which case n is 1.
- the hydroxy carboxylic acid comprises at least one of the acids L- ⁇ - hydroxy-isocaproic acid, ⁇ -hydroxy- ⁇ -methyl valeric acid and L- ⁇ -hydroxy-isovaleric acid.
- One, two or three of the hydroxy groups in the glycerol molecule may be esterified with hydroxy carboxylic acid.
- one or two of the hydroxy groups will be esterified with hydroxy carboxylic acid, however, where ⁇ in the remaining hydroxy group or groups is/are esteri ⁇ fied with one or more fatty acids having from 4 to 22 carbon atoms in its/their carbon chains.
- the glycerol ester or esters may be derived from glyce- rides in a pharmaceutically acceptable fat which has been transesterified with one or more of the hydroxy carboxylic acids.
- the glycerol esters used in accordance with the inven ⁇ tion may be prepared by pure organic synthesis or semi- synthetically, by chemical transesterification of a natulral triglyceride having one branched hydroxy car ⁇ boxylic acid. Transesterification can also be effected biochemically, with the aid of an enzyme system together with triglyceride and branched hydroxy carboxylic acid.
- a semi-synthetic transesterification can be effected, for instance, on the basis of a vegetable or animal oil and a branched hydroxy carboxylic acid, and with the use of a catalyst, such as sodium ethoxide.
- esters A purely organic-chemical synthesis will often result in uniform esters, which also applies to polyol esters. Statistically, uniform esters are also obtained when transesterifying with sodium ethoxide. An enzymatic transesterification, on the other hand, is often posi ⁇ tion-specific, for instance then for the positions 1 and 3.
- SUBSTITUTE SHCE One method of obtaining the desired structure when transesterifying, is to use various lipases with addi ⁇ tions of the fatty acid to be incorporated.
- An example of one such enzyme is Lipozyme , available commercially from Novo Industrier, Copenhagen, Denmark. This enzyme, which is available in an immobilized form, so that it can be used repeatedly, is of microbiological origin (Mucor miehei), and is specifically lipolytic in posi ⁇ tions 1 and 3 of the triglyceride.
- the vegetable or animal oil or fat used as the starting material in the transesterification process must be pharmaceutically acceptable.
- suit ⁇ able oils in this connection are soya oil, sunflower oil, Oenothera bie nnis oil, oil from Borago (Borage), or blackcurrent oil and fish oils.
- Energy substrates produced in accordance with the inven ⁇ tion will suitably contain between 1 and 100 percent by weight of esterified hydroxy carboxylic acid, and then preferably between 20 and 60 percent by weight.
- Such an emulsion may comprise, for instance, 0.1-50% w/w in water of a pharmaceutically acceptable oil or fat, 0.1-6% w/w of phospholipids prepared from eggs or soya beans, 0.1-4.5% w/w of glycerol or some other isotonic sub- stance, and for instance a carbohydrate such as glucose or fructose.
- Phosphatidyl glycerol and/or phosphatidic acid, fatty acids (8-22 carbon atoms), and alkali salts of fatty acids, for instance Na-oleate may also be in ⁇ cluded in a total concentration of 0.1-5% as additional emulsion stabilizers.
- SUBSTITUTE SHEJET Emulsions for use as a nutrient substrate in accordance with the present invention are prepared in accordance with conventional pharmaceutic practice, in a manner well known to the person skilled in this art.
- the constituents used are of a pharmaceutically non-objectionable character.
- a protective gas e.g. nitrogen gas
- the resultant emulsion should also be stored in a protec ⁇ tive-gas environment.
- the emulsion is administered parenterally, e.g. intravenously, the water used must also be sterile and free of pyrogens.
- the emulsions prepared in accordance with the invention may also contain additional nutrients, such as amino acids, carbohydrates and other fat substances of vege- table, animal or synthetic origin.
- the emulsions may also contain vitamins, trace elements and salts. This will enable the triglycerides used in accordance with the invention to be included in a system which will allow a complete nutrient supply to be administered enterally or parenterally.
- the emulsions When the inventive emulsions are to be administered parenterally, the emulsions will preferably have an average particle size of beneath 0.5 micron. A manner of achieving this is described in the following examples (Nos. 10 and 11).
- Example 11 also illustrates how mammals are able to utilize the inventive triglycerides biologically as energy substrates instead of glucose and fat from a conventional fat emulsion.
- the single figure of the accompany drawing is a com ⁇ parison diagram which compares the increase in weight of a group of rats administered with nutrient in the form of an energy substrate prepared in accordance with the invention, with the weight increase of a control group to which conventional nutrient was administered parenterally.
- Example 2 26.55 g of L- ⁇ -hydroxy leucine were dissolved in 88.9 g triolein in a nitrogen-gas atmosphere at +65 C, while stirring the system. 0.8 ml of distilled water and 11.55 g of Lipozym ⁇ *--* were added to the solution. The reaction continued over 4 calender days, during which a further 0.8 ml of distilled water was added to the solution on day 2 and day 4. At the end of the fourth day period, the enzyme was filtered-off and the crude product dissolved in cold petroleum ether (875 ml) and stored at -20°C for 1 calender day.
- the resultant preci- pitate of free L- ⁇ -hydroxy leucine was then filtered-off and the filtrate evaporated under vacuum conditions to constant weight.
- the precipitate was then extracted in distilled water twice (400 ml), in order to isolate the final residues of hydroxy leucine. Analysis of the precipitate showed that 49.5% of the L- ⁇ -hydroxy leucine introduced to the system was present in a chemically bound form, and when recalculated to new triglyceride was found to comprise 38.4% of residual triglycerides.
- Example 6 265 g of L- ⁇ -hydroxy valine were dissolved in 500 g of pure soybean oil, in a nitrogen-gas atmosphere at +65 C, while stirring the system. The reaction continued for 4 calender days, during which 1 ml of distilled water was added to the solution on days 2, 3 and 4. At the end of the 4-day period, the enzyme was filtered off and the crude product dissolved in 5000 ml of cold petroleum ether. The solution was allowed to stand for 1 calender day in cold conditions. The resultant precipitate of free L- ⁇ -hydroxy valine was then filtered off and the filtrate evaporated under vacuum conditions to constant weight. The resultant oil was decolourized with the aid of a known method using 10% fullers / earth and 1% acti ⁇ vated carbon-. The oil was then treated with soda in accordance with known techniques, in order to extract free fatty acids. The oil was finally dried with dry
- Example 7 265 g of L- ⁇ -hydroxy valine were dissolved in 500 g of refined soybean oil in a nitrogen-gas atmosphere, at +62°C, while stirring the system. 4 ml of distilled water and 76.5 g of Lipozyme ⁇ were added to the solu ⁇ tion. The reaction continued for 4 calender days, during which a further 2 ml of distilled water were adde * * d to the solution on days 2, 3 and 4. The enzyme was then filtered off and the crude product dissolved in 5000 ml of cold petroleum ether, and the solution was allowed to stand for 1 calender day, in cold conditions.
- the resul- tant precipitate of free L- ⁇ -hydroxy valine was then filtered off and the filtrate obtained was evaporated under vacuum conditions to constant weight.
- the resul ⁇ tant oil was decolourized with the aid of a known method, using 20% fullers' earth and 1% activated car- bon.
- the oil was then treated with soda in accordance with a known technique, in order to isolate free fatty acids.
- the oil was finally dried with dry sodium sul ⁇ phate. Upon completion of this stage, the amount of free fatty acids present was measured as 5.5 mmol/kg.
- the yield calculated on the incorporated amount of L- ⁇ - hydroxy valine was 47.6% of the stoichiometric quantity, which when recalculated to new triglyceride was found to comprise 36.4% of the total amount of triglycerides.
- Oil on which L- ⁇ -hydroxy leucine was bound and which was prepared in accordance with the processes described in the previous examples was mixed with refined soybean oil in the proportions of 114.7/85.3.
- the mixture was sterile-filtered with the aid of a sterile filter 0.45 ⁇ m of the type Millipore**H 30.0 g of egg-yolk phospholipides were dissolved in 400 ml of the aforesaid sterile oil, at 60°C. 88.8 g of glycerol (50% in water) were dissolved in about 1477 ml of heated distilled water (+80 C) .
- the oil-phospholipid solution was preemulsified with the aid of a Janke-Kunkel Ultra- Turrax over a period of 10 minutes, wherein 4.0 ml of a 1 M aqueous solution of sodium hydroxide were also added.
- the resultant precursory emulsion was finally emulsified in a valve-homogenizer of the type Manton-
- the resultant emulsion was dispensed into glass flasks or bottles, under vacuum conditions and in a nitrogen-gas atmo ⁇ sphere, and the flasks sealed with rubber stoppers and capsules. The emulsion was then heat-sterilized in accordance with an accepted technique.
- a central vein catheter was implanted surgically into male rats of the strain Sprague-Dawley, weighing 180-190 g. The catheters were protected by a saddle (Roos et al, 1981). Nutrients were administered parenterally and comprised the following standard program or formula:
- NPC non-protein calories 1098 kJ/kg body weight and 24 hours
- the ratio between glucose and fat was 70/30 energy percent.
- the energy percentage from the energy substi ⁇ tute during the test period was about 15% of NPC.
- the TPN-mixture was obtained by mixing Vamirr- ⁇ 14 (a solution of essential and non-essential amino acids for paren ⁇ teral nutrient administration; electrolyte free), glucose solution 50% and Intralipi ⁇ *** ⁇ 20% in suitable proportions, with the addition of adequate quantities of electrolytes, trace elements and vitamins.
- the rats were divided randomly into 3 groups, with 6 animals in each group.
- One group was treated with the same TPN-progra as earlier (reference group).
- the other groups were administered with L- ⁇ -hydroxy leucine and L- ⁇ - hydroxy valine in bound form respectively (prepared in accordance with the process described, inter alia, in Examples 6, 7, 8) as new fat emulsion (Examples 9 and 10).
- the amount of bound, branched hydroxy acid was administered in replacement of an equivalent amount of glucose energy.
- the TPN-program was the same as that used for the reference group.
- the amount of bound L- ⁇ -hydroxy leucine administered equalled 2.0 g/kg body weight and day, while the amount of L- ⁇ -hydroxy valine administered corresponded to 1.8 g/kg body weight and day. This corresponds respectively to 4.5 g and 4.3 g of new triglyceride per kg of body weight and day, with L- ⁇ -hydroxy leucine and L- ⁇ -hydroxy valine in the 1 and 3 positions respectively of a
- SUBSTITUTE SHEET structurized lipid In total, the animals received daily 8-10 g of fat for each kg of body weight. About half the fat dosage consisted of new triglyceride. The animal experiment then continued for 9 consecutive calender days, during which the weight of the animals was recorded daily and the urine secreted was collected and frozen. At the end of the test period, the rats were killed, by heart puncture while under a pentobarbital anesthetic. An autopsy was then performed with microscopic examination. The body organs were sent to a laboratory for pathological assay.
- n the number of test occasions (number of rats in each group x number of test days)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Le substrat énergétique décrit, qui est destiné à être administré à des mammifères comme substance nutritive à l'état catabolique, se caractérise en ce qu'il contient au moins un ester de glycérol et au moins un acide carboxylique hydroxy comportant une chaîne de carbone ramifiée.The energy substrate described, which is intended to be administered to mammals as a nutritive substance in the catabolic state, is characterized in that it contains at least one glycerol ester and at least one hydroxy carboxylic acid comprising a branched carbon chain .
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8803142A SE8803142L (en) | 1988-09-07 | 1988-09-07 | NEW ENERGY SUBSTRATE |
SE8803142 | 1988-09-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0389598A1 true EP0389598A1 (en) | 1990-10-03 |
Family
ID=20373249
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP89850290A Pending EP0367734A1 (en) | 1988-09-07 | 1989-09-06 | Energy substrate containing hydroxycarboxylic acid and a glycerol ester |
EP89910235A Withdrawn EP0389598A1 (en) | 1988-09-07 | 1989-09-06 | Energy substrate containing hydroxy carboxylic acid and glycerol ester |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP89850290A Pending EP0367734A1 (en) | 1988-09-07 | 1989-09-06 | Energy substrate containing hydroxycarboxylic acid and a glycerol ester |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP0367734A1 (en) |
JP (1) | JPH03501028A (en) |
AU (1) | AU4220789A (en) |
SE (1) | SE8803142L (en) |
WO (1) | WO1990002548A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5028440A (en) * | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
DE4116004C2 (en) * | 1991-05-16 | 1993-09-30 | Fresenius Ag | nutrient preparation |
US5420335A (en) * | 1993-09-30 | 1995-05-30 | Birkhahn; Ronald H. | Parenteral nutrients based on watersoluble glycerol bisacetoacetates |
WO1995009144A1 (en) * | 1993-09-30 | 1995-04-06 | Eastman Chemical Company | Nutritive water soluble glycerol esters of hydroxy butyric acid |
WO1995009145A1 (en) * | 1993-09-30 | 1995-04-06 | Eastman Chemical Company | NUTRITIVE GLYCEROL ESTERS OF β-ACYLOXY BUTYRATES |
CA2338090C (en) | 1998-07-22 | 2009-07-14 | Metabolix, Inc. | Nutritional and therapeutic compositions of 3-hydroxyacids for increasing blood ketone bodies |
FI20045395A (en) * | 2004-10-21 | 2006-04-22 | Elmomed Ltd Oy | Nutritional supplement and its use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4665057A (en) * | 1983-03-22 | 1987-05-12 | Deanna Nelson | Nutrient monoesters |
EP0168425A4 (en) * | 1984-01-16 | 1989-03-09 | Baxter Travenol Lab | Parenteral nutrition with medium and long chain triglycerides. |
-
1988
- 1988-09-07 SE SE8803142A patent/SE8803142L/en not_active Application Discontinuation
-
1989
- 1989-09-06 EP EP89850290A patent/EP0367734A1/en active Pending
- 1989-09-06 WO PCT/SE1989/000473 patent/WO1990002548A1/en not_active Application Discontinuation
- 1989-09-06 AU AU42207/89A patent/AU4220789A/en not_active Abandoned
- 1989-09-06 EP EP89910235A patent/EP0389598A1/en not_active Withdrawn
- 1989-09-06 JP JP1509653A patent/JPH03501028A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9002548A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP0367734A1 (en) | 1990-05-09 |
WO1990002548A1 (en) | 1990-03-22 |
AU4220789A (en) | 1990-04-02 |
SE8803142L (en) | 1990-03-08 |
SE8803142D0 (en) | 1988-09-07 |
JPH03501028A (en) | 1991-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5093044A (en) | Triglyercide nutrient for humans and animals | |
DE3785667T2 (en) | ADDITIONAL FOOD OR THERAPY FOR PERSONS WITH RISK OR TREATMENT FOR ARTERIOSCLEROTIC VASCULAR, CARDIOVASCULAR AND / OR THROMBOTIC DISEASES. | |
Holt | The roles of bile acids during the process of normal fat and cholesterol absorption | |
Glavind et al. | On the digestion and absorption of lipoperoxides | |
US5292722A (en) | Intravenous solution that diminishes body protein loss | |
JPH02191220A (en) | Drug containing inositol triphosphate against abnormal level of lipoprotein | |
EP0389598A1 (en) | Energy substrate containing hydroxy carboxylic acid and glycerol ester | |
US3197368A (en) | Process for the preparation of natural choline phosphoric acid diglyceride ester compounds | |
EP0457314A1 (en) | Nutrient compositions containing peptides | |
JPH06511384A (en) | Nutrition for humans and animals | |
Ardawi | Glutamine-synthesizing activity in lungs of fed, starved, acidotic, diabetic, injured and septic rats | |
CA2340223A1 (en) | Nutritional compositions for preventing or treating hyperlipoproteinemia | |
Goodridge et al. | The effect of prolactin on lipogenesis in the pigeon. In vitro studies | |
Grancher et al. | Studies on the tolerance of medium chain triglycerides in dogs | |
JPH08283163A (en) | Enantiomer reinforced nutrition energy substrate | |
Wolfram | Medium‐chain triglycerides (MCT) for total parenteral nutrition | |
DE3781268T2 (en) | USE OF GROWTH HORMONES FOR NITROGEN RETENTION IN HYPOCALORIC CONDITIONS. | |
US20020172710A1 (en) | Clinical use of liposome technology for the delivery of nutrients to patients with the short bowel syndrome | |
Birkhahn et al. | Potential of the monoglyceride and triglyceride of DL-3-hydroxybutyrate for parenteral nutrition: synthesis and preliminary biological testing in the rat | |
EP0363337A1 (en) | Energy substrate containing hydroxycarboxylic acid | |
WO1992019237A1 (en) | Use of a lipid for production of a pharmaceutical enteral preparation for treatment of lipid malabsorption | |
Gnoni et al. | Mechanism of triiodothyronine stimulation on microsomal fatty acid chain elongation synthesis in rat liver | |
WO1990002726A1 (en) | Alternative energy substrate | |
Krebs | Some general considerations concerning the use of carbohydrates in parenteral nutrition | |
EP0711155B1 (en) | Amino acid supplement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19900423 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
XX | Miscellaneous |
Free format text: VERBUNDEN MIT 89850290.1/0367734 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) DURCH ENTSCHEIDUNG VOM 27.02.91. |
|
17Q | First examination report despatched |
Effective date: 19910611 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: KABI PHARMACIA AB |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19930514 |